anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Bronchiolitis is a common admitting diagnosis for children less than 1 year of age. Although bronchiolitis has a high prevalence, there is a lack of a unified inpatient treatment plan beyond supportive care of supplemental oxygen and intravenous hydration. There have been many different approaches to the treatment of bronchiolitis, but none have conclusively proven to be beneficial. Several early studies show promise for the use of nebulized hypertonic saline, however the majority of these studies are done outside the United States and with adjunctive therapy. To date, the data suggesting that nebulized hypertonic saline is safe and effective for reducing length of stay in bronchiolitis is strong but not generalizable for the United States. The objective of this study is to conduct the first double-blind, randomized controlled trial in the United States of nebulized hypertonic saline without adjunctive therapy, including infants with bronchiolitis, including those with prior history of wheeze, to assess the effect on length of stay and therefore resource utilization.
The present invention relates to nucleic acid molecules, preferably genomic sequences, encoding an ATP-gated ion channel P2X7R which contain a mutation in the 5'UTR or 3'UTR regions, a mutation in exon 3, 5, 6, 8 or 13 or in introns 1, 3, 4, 5, 6, 7, 9, 11 or 12 or a deletion in exon 13, which allow to diagnose affective disorders. The invention further relates to polypeptides encoded by said nucleic acid molecules vectors and host cells comprising said nucleic acid molecules as well as to methods for producing polypeptides encoded by said nucleic acid molecules. The present invention also provides antibodies specifically directed to polypeptides encoded by said nucleic acid molecules and aptamers specifically binding said nucleic acid molecules. Additionally, primers for selectively amplifying said nucleic acid molecules are provided in the present invention as well as kits, compositions, particularly pharmaceutical and diagnostic compositions comprising said nucleic acid molecules, vectors, polypeptides, aptamers, antibodies and/or primers. Moreover, the present invention relates to methods for diagnosing affective disorders associated with a nonfunctional P2X7R protein, an altered ATP-gating of the P2X7R protein, an over- or underexpression of the P2X7R protein or associated with the presence of any one of the aforementioned nucleic acid molecules or polypeptides encoded thereby. Additionally, the present invention relates to uses and methods for treating affective disorders employing a functional or non-functional ATP-gated ion­-channel P2X7R. The present invention also relates to uses of modulators of P2X7R activity for treating affective diseases. Furthermore, the present invention also relates to methods for identifying and characterizing compounds which are capable of specifically interacting with or altering the characteristics of the polypeptides of the present invention as well as to methods for the production of pharmaceutical compositions.
PURPOSE: An antibiotic composition containing green tea extract, papaya extract, chitosan, and phytospingosine is provided to ensure excellent antibiotic effect to acne-inducing bacteria. CONSTITUTION: An antibiotic composition contains green tea extract, papaya extract, chitosan and phytospingosine as active ingredients. A composition for preventing or treating acne contains green tea extract, papaya extract, chitosan, phytospingosine as active ingredients. The composition contains the ingredients in 0.1-20 weight parts. The composition additionally contains carbapol and KOH. The bacteria are antibiotic-resistant bacteria. The composition is an external use skin composition. The external use skin composition is used in the form of solution, suspension, emulsion, paste, gel, cream, lotion, powder, and soap.
In the treatment of infantile spasms, Acthar Gel must be administered intramuscularly using the Acthar gel vial. Do not use the Acthar Gel single-dose pre-filled SelfJect injector for the treatment of infantile spasms. The recommended regimen is a daily dose of 150 U/m2 (divided into twice daily intramuscular (IM) injections of 75 U/m2) administered over a 2-week period. Dosing with Acthar Gel should then be gradually tapered over a 2-week period to avoid adrenal insufficiency. The following is one suggested tapering schedule: 30 U/m2 in the morning for 3 days; 15 U/m2 in the morning for 3 days; 10 U/m2 in the morning for 3 days; and 10 U/m2 every other morning for 6 days.

Acthar Gel is typically dosed based on body surface area (BSA). For calculation of body surface area, use the following formula:
Several lines of evidence show energy metabolism and redox dysregulation in bipolar disorder and psychotic disorders. Ketogenic interventions targeting energy metabolism are promising therapeutic approaches to improve mood and psychosis in bipolar disorder and other psychotic disorders. Early intervention is also critical to helping people achieve their goals for recovery after a first episode. Investigators aim to use multimodal imaging and metabolic measures to study the effects of a ketogenic diet intervention on energy metabolism and psychiatric symptoms in individuals with first episode bipolar disorder and schizoaffective disorder. This 12-week randomized controlled trial will assess the benefits of a ketogenic diet in combination with treatment as usual compared to a standard diet. Investigators will measure the effects of nutritional ketosis on brain redox and energy metabolism and other neurometabolic markers using magnetic resonance spectroscopy. Furthermore, investigators will measure the effects of the ketogenic diet on mood and psychotic symptoms and metabolic measures such as insulin resistance.
The present invention belongs to the technical field of medicines, which relates to a Chinese patent medicine for curing diabetes, namely a ginseng flower tea for treating diabetes and a preparation method thereof. The present invention is characterized in that the present invention is prepared from 13 kinds of Chinese herbal medicines such as dodder, ginseng, trichosanthes root, rhizoma anemarrhenae, safflower, gypsum, green tea, wolfberry bark, reed rhizome, polygonatum, astragalus root, kudzuvine root and platycodon root according to percentage by weight via selection, decoction in water for three times, combined decoction and filtration. Filter liquor is concentrated into clear paste with the relative density of 1.12 to 1.20 and the temperature of 60 DEG C. The clear paste is dried under the temperature of 80 DEG C, pulverized and granulated to obtain chocolate brown coarse powdery medicinal tea with the odor of tea fragrance and slightly bitter and pungent taste. The ginseng flower tea for treating diabetes has the advantages of high medicinal activity, quick therapeutic effect and favourable effect on treating diabetes and can obviously improve the clinical symptoms of diabetics, such as mouth and throat dryness, polydipsia, excessive thirst, polyuria, myasthenia of limbs, dizziness, etc. The present invention particularly has good therapeutic effect on diabetic lower limb edema and has the functions of nourishing Yin, tonifying the kidney and benefiting qi for promoting production of fluid. The present invention is suitable for the symptoms of II type diabetes, such as deficiency of both vital energy and yin and deficiency of kidney qi.
The efficacy of FIASP was evaluated in 3 randomized, active-controlled trials of 18 to 26 weeks duration in adults and one randomized, active-controlled, treat-to-target trial of 26 weeks duration in pediatric patients. 

In total 1,224 adult subjects (N=763 with type 1 diabetes mellitus; N=461 with type 2 diabetes mellitus) and 519 pediatric subjects with type 1 diabetes mellitus were randomized to FIASP. In adult and pediatric patients with type 1 diabetes mellitus, mealtime FIASP and postmeal FIASP led to non-inferior glycemic control compared to mealtime NovoLog, both in combination with basal insulin. In adult patients with type 2 diabetes mellitus, mealtime FIASP provided non-inferior glycemic control compared to mealtime NovoLog, both in combination with metformin. In addition, mealtime FIASP in a basal-bolus regimen with metformin also provided statistically significant improvement in the overall glycemic control compared to basal insulin therapy alone with metformin in adult patients with type 2 diabetes mellitus. 

In adults with type 1 diabetes mellitus (N=472), FIASP led to non-inferior glycemic control compared to NovoLog when both were administered by continuous subcutaneous insulin infusion (CSII) pump.
Professional mechanical plaque removal and submarginal instrumentation using titanium curettes will be performed in the non-surgical treatment of peri-implant mucositis with KMW \< 2 mm. Free gingival grafting will be done one month after the non-surgical treatment.
Post-induction hypotension (PIH) is a common event due to general anesthesia in patients undergoing surgery. It is described as hypotension occurring during the period from induction of general anesthesia to initiation of incision. A universal definition of intraoperative hypotension is lacking, leading to inconsistent rates of occurrence for PIH. According to Yoshimura et al., PIH occurs in 34% of patients using the mean arterial pressure (MAP) definition of \< 55 mmHg, whereas Maheshwari found PIH in 53% of patients using a MAP definition of \< 65 mmHg. Furthermore, Maheshwari et al. demonstrated that PIH was an independent risk factor for postoperative major complications such as myocardial injury, cerebrovascular events, and acute kidney injury.

If high-risk patients for PIH could be identified we might potentially prevent PIH. In a systematic review, Chen et al. pointed out that the risk factors associated with PIH were ASA (American Society of Anesthesiologists) III-V, advanced age, emergency cases, hypovolaemia, long-term use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, use of propofol and high-dose of opioid. This study suggests that PIH may be the result of an interaction between the anesthetic agent and the cardiovascular condition of the patient. Conditions such as moderate-to-severe aortic regurgitation, moderate-to-severe mitral regurgitation, regional wall motion abnormalities, and echocardiography findings (e.g. elevated ratio of peak early diastolic transmitral flow velocity to annular velocity) have been identified as PIH-independent risk factors.

End-systolic elastance (Ees) is a measure of the contractile state of the left ventricle (LV). It represents the relationship between LV end-systolic pressure (LVESP) and end-systolic volume (ESV). Effective arterial elastance (Ea) is a measure of the total arterial load on the LV and is calculated as the ratio of LVESP to stroke volume (SV). Ventricular-arterial coupling (VAC), assessed by the ratio Ea/Ees, describes the interaction between the LV and arterial system. VAC reflects the interplay between the changes in LV contractility (Ees) and changes in arterial load (Ea) to maintain optimal LV performance.

Aktas et al. analyzed Ea as a predictor of PIH. The results of this study showed that pre-induction Ea had excellent predictability of hypotension. However, Ees values were not determined, thus making it speculative to conclude that pre-induction VAC is impaired in patients with high Ea. There are no studies available that assessed the role of preoperative VAC in predicting PIH. Therefore, we will investigate the relationship between the preoperative Ea/Ees ratio and the incidence of PIH (: hypotension being defined as MAP \< 65 mmHg).
Obesity is associated with important changes in cardiac energetics and function, and an increased risk of adverse cardiovascular outcomes. Multi-nuclear MRS and MRI techniques have the potential to provide a comprehensive non-invasive assessment of cardiac metabolic perturbation in obesity. A rat model of obesity was created by high-fat diet feeding. This model was characterized using in vivo hyperpolarized [1-13C]pyruvate and [2-13C]pyruvate MRS, echocardiography and perfused heart 31P MRS. Two groups of obese rats were subsequently treated with either caloric restriction or the glucagon-like peptide-1 analogue/agonist liraglutide, prior to reassessment. The model recapitulated cardiovascular consequences of human obesity, including mild left ventricular hypertrophy, and diastolic, but not systolic, dysfunction. Hyperpolarized 13C and 31P MRS demonstrated that obesity was associated with reduced myocardial pyruvate dehydrogenase flux, altered cardiac tricarboxylic acid (TCA) cycle metabolism, and impaired myocardial energetic status (lower phosphocreatine to adenosine triphosphate ratio and impaired cardiac ΔG~ATP). Both caloric restriction and liraglutide treatment were associated with normalization of metabolic changes, alongside improvement in cardiac diastolic function. In this model of obesity, hyperpolarized 13C and 31P MRS demonstrated abnormalities in cardiac metabolism at multiple levels, including myocardial substrate selection, TCA cycle, and high-energy phosphorus metabolism. Metabolic changes were linked with impairment of diastolic function and were reversed in concert following either caloric restriction or liraglutide treatment. With hyperpolarized 13C and 31P techniques now available for human use, the findings support a role for multi-nuclear MRS in the development of new therapies for obesity.
Genital prolapse is a very common functional pathology that affects 30% of women. The functional impact of prolapse is highly variable and may lead patients to consider surgery. Surgery for laparoscopic genital prolapse (laparoscopy) is a common practice. The placement of prostheses on the anterior and posterior walls of the vagina is sort of "estimated", performed without any quality control . This technique is associated with a high rate of patient satisfaction (90% satisfaction), but a risk of anatomical recurrence in 20-30% of cases and a risk of reoperation for relapse in 3% of cases. It is likely that the lower the intervesico-vaginal prosthesis, the lower the risk of cystocele relapse is important.The postoperative ultrasound visualization of prostheses placed in promontofixation is possible: they appear hyperechoic. In particular, in anterior, where a prosthesis is placed between the vagina and the bladder, it is possible to verify that this prosthesis supports the entire bladder base.Thus, it may be possible to check the correct position of the prostheses intraoperatively. If studies were conducted postoperatively, to the best of our knowledge, no study has been conducted on the value of an intraoperative ultrasound control.
Functional imaging for localization in biological tissue entails measuring a response in the tissue ( 240 ) to electromagnetic radiation. A catheter ( 200 ) for real-time monitoring of cardiac ablation is employed to distinguish a hemorrhage zone ( 232 ) from the sandwiching necrotic and healthy tissue, or to distinguish exogenous photoacoustic contrast agent from bordering native tissue. A pair of wavelengths is selected for differential absorption ( 244 ) of the radiation in, correspondingly, the hemorrhage zone or where the contrast agent exists, and relatively similar absorption elsewhere. Near infrared laser or LED light may be used photoacoustically to serially acquire (S 310 , S 320 ) the two datasets to be compared, each representative of a time waveform. Alternatively, acquisition is for a pair of wavelength bands of microwave-induced thermoacoustic data. In either case, the members of the dataset pair are combined ( 110, 122 ) by subtraction or division to effect the piece-wise cancellation/enhancement for display ( 218 ) of the resulting signal in real time.
According to the present invention, an oral solid formulation is coated with a rapid disintegration gel coating that contains an acidic substance, a carbonate, and a polymer that turns into a gel through contact with moisture. As a result, while being a formulation that disintegrates in the oral cavity, the oral solid formulation can be easily swallowed and delay of dissolution of active ingredients from the oral solid formulation is suppressed. This oral solid composition comprising a gel coating is inhibited from undergoing discoloration, when being hermetically packaged or packaged in an airtight manner together with a desiccant. By setting the glycerin concentration in the gel coating to 2 mass% or less, growth of mold is unlikely to occur. By forming the gel coating using a coating liquid in which a polymer that turns into a gel through contact with moisture is dispersed, the gel coating can be formed in a short period of time even if the blended amount of said polymer is increased. The gel coating, which contains TiO 2  at a concentration of 20 mass% or less, can be marked in a manner identifiable through ultraviolet laser irradiation.
Participants with body weight greater than or equal to (≥) 20 kilogram (kg) will receive the recommended dose of leuprorelin 11.25 milligram (mg), injection, subcutaneously, once every 3 months for 6 months. Participants with body weight less than (\<) 20 kg will receive leuprorelin 5.625 mg, injection, subcutaneously, once every 3 months for 6 months.
BACKGROUND: Cell Migration Inducing Hyaluronidase 1 (CEMIP) is a protein that plays regulatory functions in a variety of cellular processes in many diseases. Nevertheless, its role and molecular mechanism in keloid hyperplasia are still elusive.
METHODS: Expressions of CEMIP and Secreted Protein acidic and Rich in Cysteine (SPARC) were detected by qRT-PCR and western blot. CCK-8 assay, along with immunofluorescence staining, was applied for the assessment of cell proliferation. The capabilities of cells to migrate and invade were evaluated utilizing wound healing and Transwell, while Extracellular Matrix (ECM) deposition was measured by immunofluorescence and western blot. The interaction of CEMIP and SPARC was predicted by the Coexpedia and PPA-red databases and verified by co-IP. Western blot was adopted for the estimation of TGF-β/Smad pathway-related proteins.
RESULTS: The data demonstrated that CEMIP expression was elevated in Keloid Fibroblasts (KF). CEMIP interference suppressed cell proliferative, migrative and invasive capabilities and ECM deposition in KF. Mechanistically, bioinformatics analysis revealed that CEMIP was co-expressed with SPARC and CEMIP protein could bind to SPARC. SPARC expression was reduced in CEMIP-silenced cells. SPARC overexpression counteracted the impacts of CEMIP silencing on cell proliferative, migrative and invasive capabilities and ECM deposition in KF. In addition, the expressions of TGF-β/Smad signaling-related proteins were decreased by CEMIP silencing via the inhibition of SPARC.
CONCLUSION: In summary, this study revealed that CEMIP modulated KF proliferation, migration, invasion and ECM deposition by TGF-β/Smad signaling through binding to SPARC.
The introduction of CFTR modulator drugs like elexacaftor-tezacaftor-ivacaftor (ETI) has transformed the management of cystic fibrosis (CF), significantly improving symptoms, lung function, and quality of life, while reducing reliance on intravenous antibiotics. However, respiratory exacerbations in the CFTR modulators era remain poorly understood from both pathophysiological and clinical perspectives. We present the case of a 20-year-old Caucasian woman with CF (F508del/L1077P) who, after three years of ETI treatment, experienced a severe episode of hemoptysis, despite being almost asymptomatic in the weeks leading up to admission, requiring bronchial artery embolization. Following ETI treatment, auscultatory findings and FEV1 changes may be less significant, making the detection of respiratory exacerbation more challenging. This highlights the need for heightened vigilance in managing such cases and underscores the challenge of diagnosing and managing exacerbations in the era of modulators. Long term real-world studies are essential to comprehend the evolving course of the disease during ETI treatment.
This is an observational study, aimed at exploring:

i) gluconeogenesis rates ii) sources of gluconeogenesis and pyruvate cycling, and iii) protein kinetics in critically ill children and adolescents, and its differences by age group, as well as in comparison to healthy adolescents. The study size will include 45 critically ill septic, pediatric patients (22 children at 5-12 years of age and 23 adolescents' at 13-19 years of age), male and females admitted to the pediatric intensive care unit (PICU) at Children's Medical Center, Dallas. The minimal subject's weight will be 17kg. Additionally, 30 healthy adolescents matched by age, gender, BMI and Tanner stage will be studied at the Clinical Translational Research Center at Zale Lipshy Hospital, to serve as healthy adolescent controls. The number of subjects includes an expected drop out rate of about 20%, in order to obtain 18 patients with complete data in each group. Patients will receive nutritional support as per standard care. This study will yield important knowledge and may lead in the future to changes in the current practice on the management of critically ill pediatric patients in the PICU.
PURPOSE:To produce the titled composite by removing active-type coagulation factor existing in a blood coagulation factor IX composite preparation. CONSTITUTION:An active-type coagulation factor existing in a blood coagulation factor IX composite preparation is removed by treating the preparation with an immobilized carrier produced by bonding a compound selected from aminobenzamidine, aminophenylguanidine and basic amino acids (e.g. arginine, lysine, etc.) to a water-insoluble carrier (e.g. cellulose, agarose, dextran, polyacrylamide, amono acid copolymer, etc.) to obtain the objective blood coagulation factor IX composite. Any coagulation factor IX composite preparation may be used as the starting material provided that the factor is originated from human plasma. The compositional ratio of the composite is preferably 0.64-1.8pts. of the factor II, 0.02-1.2pts. of the factor VII and 0.44-2.3pts. of the factor X based on 1pt. of the factor IX. EFFECT:The objective composite can be produced with a simple treatment process without necessitating complicate processes such as addition of stabilizer, etc.
The present invention provides a helicid soft capsule which is composed of liquid medicine and capsule wall materials. The present invention is characterized in that the liquid medicine contains 50 to 200 mg of helicid whose particle diameter is smaller than 200 mu m by weight and the rest is medicinal or edible auxiliary materials used as solvent substrates. Since raw material, namely helicid, is ultra-finely refined in advance, the specific surface area of helicid is increased so that the helicid soft capsule has the characteristics of rapid dissolution, good biological availability, etc.; in addition, the helicid soft capsule contactd with the intestinal wall easily to accelerate the absorption of a human body, and therefore, the helicid soft capsule fully exerts the effects of tranquilization and sedation. In addition, the helicid soft capsule also has the advantages of preferable external appearance, stable effect and obvious sedation effect, and takes effect in 2 hours; the capsule improves sleep quality, obviously reduces waking frequency at night and has strong anti-inflammatory effect. Compared with the conventional tablets, the biological availability of the present invention is increased by 10 to 59%.